Triple-negative breast cancer
Smarter science, sharper strategy: Expert insights from ASCO® 2026
As the oncology landscape continues to evolve, life sciences organizations face a growing challenge: how do you communicate increasingly complex science in a way that creates meaningful engagement?
AstraZenca’s Etcamah combination therapy given FDA Accelerated Approval for breast cancer
The approval was based on phase 3 trial results showing a 56% risk reduction in disease progression
AstraZeneca and Daiichi Sankyo’s Enhertu plus pertuzumab approved in EU as first-line treatment for breast cancer
This is the first new regimen in more than a decade for first-line treatment for this type of breast cancer
MSD and Moderna announce potential new vaccine for melanoma
The mRNA-based therapy, used with Keytruda, is designed specifically for each patient
US FDA accepts supplemental Biologics License Application for Merck’s Enflonsia
The treatment is to protect children under two years of age from respiratory syncytial virus
Permission to pause: making treatment breaks part of the cancer care conversation
Exploring how empathetic, patient-centred communication can make planned treatment breaks easier to discuss as part of cancer care.
Key takeaways from ASCO® 2026
Following ASCO® 2026, Inizio's experts have shared their perspectives across three thought leadership articles, each exploring a different aspect of what this year's congress revealed for pharmaceutical organisations. Together, they...
Gilead’s Trodelvy approved by EC as first-line treatment for metastatic triple-negative breast cancer
TNBC is the most aggressive type of breast cancer and has historically been difficult to treat
Webcast | Smarter science, sharper strategy: Expert perspectives from ASCO® 2026
Key insights from ASCO® 2026, including oncology trends, scientific highlights, and strategies for smarter congress engagement.
Pfizer and Innovent Biologics agree on deal worth up to $10.5bn
The companies plan to research and develop 12 new cancer treatments
One-carbon Therapeutics collaborates with Tempus in cancer treatment
The treatment is currently being evaluated in a phase 1/2 multicentre clinical study
Gilead to acquire Tubulis for up to $5bn
The acquisition builds on Gilead’s oncology pipeline, focused on addressing areas of high unmet need